C030034I22Rik Inhibitors
C030034I22Rik, originating from the RIKEN cDNA C030034I22 gene, plays a vital role in cellular processes, potentially encompassing gene expression regulation. Despite the absence of identified direct inhibitors for C030034I22Rik, exploration into potential inhibitors targeting key signaling pathways provides a foundation for future investigations. The PI3K-AKT, MAPK/ERK, TGF-β, and JNK pathways emerge as critical players influencing C030034I22Rik. These pathways collectively contribute to cellular responses and gene expression dynamics associated with this protein.
The function of C030034I22Rik is intricately linked to these pathways, where PI3K-AKT regulates cellular survival and proliferation, MAPK/ERK controls cell growth and differentiation, TGF-β influences cellular homeostasis, and JNK pathway modulates stress responses. The intricate interplay of C030034I22Rik with these signaling cascades necessitates further investigation to unveil the specific mechanisms governing its function and potential avenues for modulation. Understanding these pathways and their interactions with C030034I22Rik will pave the way for targeted interventions, shedding light on the regulatory intricacies of this enigmatic protein.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, recognized as a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K-AKT pathway to potentially influence cellular processes linked to C030034I22Rik, altering the landscape of gene expression and regulatory mechanisms associated with this protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, acting as a p38 MAP kinase inhibitor, may indirectly influence C030034I22Rik by altering the dynamics of cellular responses crucial for this enigmatic protein through modulation of the MAPK pathway, particularly p38 MAP kinase. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, envisages indirect impacts on C030034I22Rik by modulating mTOR-dependent cellular processes, potentially altering the landscape of gene expression and the regulatory mechanisms associated with this protein. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, may indirectly influence C030034I22Rik by suppressing c-Jun N-terminal kinase activity, impacting gene expression dynamics associated with this enigmatic protein through modulation of cellular stress responses. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, an MEK inhibitor, may potentially influence C030034I22Rik by altering the MAPK/ERK pathway. Its inhibition of MEK1 could impact the regulatory mechanisms of this protein, leading to alterations in gene expression dynamics. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a selective inhibitor of the TGF-β type I receptor ALK5, may indirectly impact C030034I22Rik by altering the signaling cascade related to the TGF-β pathway. This modulation could potentially influence the regulatory mechanisms associated with C030034I22Rik, affecting gene expression dynamics. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an AKT kinase inhibitor, modulates the PI3K-AKT pathway to intricately influence cellular processes linked to C030034I22Rik. Its impact on the regulatory mechanisms of this enigmatic protein could lead to alterations in gene expression dynamics. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745, envisioned as a JAK2 inhibitor, may impact C030034I22Rik through downstream STAT signaling, potentially altering cellular responses linked to the protein's regulatory mechanisms. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB202190, a p38 MAP kinase inhibitor, may indirectly influence C030034I22Rik by disrupting p38 MAP kinase activity. The disruption of this kinase, a key regulator implicated in gene expression dynamics, could impact the regulatory mechanisms of C030034I22Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K-AKT pathway to influence cellular processes linked to C030034I22Rik, potentially altering the landscape of gene expression and regulatory mechanisms associated with this protein. | ||||||